Bank of New York Mellon
KLRS

Bank of New York Mellon’s Kalaris Therapeutics KLRS Stock Holding History

Bank of New York Mellon’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,931
Closed -$120K – 4282
2024
Q1 		$120K Sell
6,931
-1,981
-22% -$32.3K ﹤0.01% 4016
2023
Q4 		$139K Buy
8,912
+1,619
+22% +$63.8K ﹤0.01% 4030
2023
Q3 		$361K Buy
7,293
+576
+9% +$39.3K ﹤0.01% 3723
2023
Q2 		$525K Buy
6,717
+1,587
+31% +$151K ﹤0.01% 3566
2023
Q1 		$465K Buy
5,130
+375
+8% +$47.8K ﹤0.01% 3527
2022
Q4 		$561K Sell
4,755
-3
-0.1% -$509 ﹤0.01% 3485
2022
Q3 		$862K Buy
4,758
+708
+17% +$110K ﹤0.01% 3280
2022
Q2 		$364K Buy
4,050
+220
+6% +$23.1K ﹤0.01% 3778
2022
Q1 		$594K Hold
3,830
– – ﹤0.01% 3611
2021
Q4 		$1.14M Hold
3,830
– – ﹤0.01% 3310
2021
Q3 		$2.21M Buy
3,830
+566
+17% +$262K ﹤0.01% 2931
2021
Q2 		$1.48M Sell
3,264
-395
-11% -$204K ﹤0.01% 3188
2021
Q1 		$1.97M Buy
3,659
+721
+25% +$606K ﹤0.01% 2934
2020
Q4 		$2.6M Buy
2,938
+647
+28% +$498K ﹤0.01% 2686
2020
Q3 		$1.45M Buy
+2,291
New +$1.56M ﹤0.01% 2880

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.43M AUM 17.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon's KLRS Position: Q2 2024 in Review

Bank of New York Mellon sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 6,931 shares — an estimated $120K sold.

Bank of New York Mellon first reported a position in KLRS in Q3 2020 and held it in 15 quarters. The position peaked at $2.6M in Q4 2020. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Bank of New York Mellon reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 6,931 Kalaris Therapeutics shares in Q2 2024, an estimated $120K.
  • Bank of New York Mellon first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 15 quarters.
  • Bank of New York Mellon's Kalaris Therapeutics position peaked at $2.6M in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.